Value based healthcare and Health Technology Assessment for emerging market countries: joint efforts to overcome barriers
Expert Review of Pharmacoeconomics & Outcomes Research · 2024
DOI: 10.1080/14737167.2024.2398482 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, 2024. Verfasst von Maximillian Otte und 7 weiteren Autor:innen. Beteiligte Einrichtung: OITBpathway V. o. G, Eupen, Belgium. Hauptthemen laut MEDLINE: Technology Assessment, Biomedical, Delivery of Health Care, Decision Making, Biosimilar Pharmaceuticals. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Abbott Products Operations AG, Swiss.
Abstract (Originalsprache)
INTRODUCTION: This paper summarizes the results from a forum of healthcare experts, academia representatives, and public agency officials from emerging and established market countries on Value-Based Healthcare (VBHC) and Health Technology Assessment (HTA). Presentations from experts provided insights into current developments and challenges, followed by interactive roundtable discussions. Emerging markets have unique healthcare systems, patient populations, resource constraints and needs. AREAS COVERED: Each roundtable explored specific topics including the role of HTA and Real-world evidence (RWE) in healthcare decision-making, challenges in biosimilar value assessment and incorporating non-price criteria reflecting context-related specifications of emerging markets such as the multifaceted nature of value in healthcare decision-making, emphasizing stakeholder perspectives and system complexities. EXPERT OPINION: RWE emerged as important in understanding biosimilar value recognition and decision-making processes, with insights into its applications and challenges. Recommendations were provided for utilizing Multi-Criteria Decision Analysis (MCDA) in pharmaceutical procurement, particularly for off-patent medicines, underscoring the importance of comprehensive evaluation frameworks and adherence to value-based principles. Overall findings suggest avenues for collaboration between industry, academia, and public agencies to address implementation barriers and promote equitable, efficient, and high-quality healthcare systems in emerging markets through public-private partnerships, joint capacity building and training initiatives, and knowledge transfers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- OITBpathway V. o. G, Eupen, Belgium.
- Department of Health Convergence, Ewha Womans University, Seoul, South Korea.
- Health ClusterNET, Amsterdam, Netherlands.
- Centre for Health Economics, University of York, York, UK.
- Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
- Center for Health Technology Assessment, Semmelweis University, Budapest, Hungary.
ORCID-Profile: Hans Peter Dauben, Jeonghoon Ahn
Förderung
- Abbott Products Operations AG, Swiss
Zitieren
APA
Otte, M., Dauben, H. P., Ahn, J., Gutierrez Ibarluzea, I., Drummond, M., Simoens, S., Kaló, Z., & Suh, D. C. (2024). Value based healthcare and Health Technology Assessment for emerging market countries: joint efforts to overcome barriers. Expert Review of Pharmacoeconomics & Outcomes Research. https://doi.org/10.1080/14737167.2024.2398482
Vancouver
Otte M, Dauben HP, Ahn J, Gutierrez Ibarluzea I, Drummond M, Simoens S, et al. Value based healthcare and Health Technology Assessment for emerging market countries: joint efforts to overcome barriers. Expert Review of Pharmacoeconomics & Outcomes Research. 2024. doi:10.1080/14737167.2024.2398482
BibTeX
@article{Otte2024,
author = {Otte, Maximillian and Dauben, Hans Peter and Ahn, Jeonghoon and Gutierrez Ibarluzea, Iñaki and Drummond, Michael and Simoens, Steven and Kaló, Zoltán and Suh, Dong-Churl},
title = {Value based healthcare and Health Technology Assessment for emerging market countries: joint efforts to overcome barriers},
journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
year = {2024},
doi = {10.1080/14737167.2024.2398482}
}
EUVIMED